Neurocrine Biosciences

NBIX

San Diego, United States· Est. 1992

neurocrine.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

NBIX · Stock Price

USD 149.59+33.88 (+29.28%)

Market Cap: $15.1B

Historical price data

Overview

Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.

NeurologicalNeuroendocrineNeuropsychiatric

Technology Platform

An integrated neuroscience platform combining deep expertise in dopaminergic, GABAergic, and neuroendocrine pathways with disciplined small-molecule discovery, clinical development, and commercial execution.

Pipeline

87 drugs in pipeline22 in Phase 3

Drug	Indication	Stage
Valbenazine Oral Capsule	Tardive Dyskinesia	Approved
Valbenazine	Schizophrenia	Approved
Valbenazine	Schizophrenia	Approved
Valbenazine + Placebo oral capsule	Tardive Dyskinesia (TD)	Approved
Valbenazine + Placebo oral capsule	Tardive Dyskinesia (TD)	Approved

Funding History

Total raised:$42M

IPO$42MUndisclosedJul 25, 1996

FDA Approved Drugs

CRENESSITYNDADec 13, 2024

INGREZZA SPRINKLENDAApr 30, 2024

Opportunities

Near-term pipeline catalysts in Huntington's disease and congenital adrenal hyperplasia offer significant label expansion and revenue growth potential.

The neuropsychiatric pipeline, targeting negative symptoms of schizophrenia, addresses a massive unmet need with no approved therapies, representing a transformative commercial opportunity.

Risk Factors

High dependence on INGREZZA revenues creates concentration risk.

Clinical trial failures or delays for key pipeline assets, particularly valbenazine in new indications or crinecerfont, could materially impact growth prospects and valuation.

Competitive Landscape

Faces direct competition in movement disorders from Teva's Austedo and generics. In emerging areas like CAH and negative symptoms of schizophrenia, competition is with other early-stage biotechs and entrenched standard-of-care treatments, requiring superior clinical data and commercial execution to secure market share.